AIMS: MicroRNA-126 (miR-126) facilitates angiogenesis and regulates endothelial cell function. Recent data suggest that miR-126 can serve as a biomarker for vascular disease. Although endothelial cells are enriched for miR-126, platelets also contain miR-126. In this paper, we investigated the contribution of platelets to the pool of miR-126 in plasma of patients with type 2 diabetes (DM2) and how this is affected by aspirin. METHODS AND RESULTS: In vitro platelet activation resulted in the transfer of miR-126 from the platelet to the plasma compartment, which was prevented by aspirin. In vivo platelet activation, monitored in patients with DM2 by measuring soluble P-selectin, correlated directly with circulating levels of miR-126. The administration of aspirin resulted both in platelet inhibition and concomitantly reduced circulating levels of platelet-derived microRNAs including miR-126. CONCLUSION: Platelets are a major source of circulating miR-126. Consequently, in patho-physiological conditions associated with platelet activation, such as diabetes type 2, the administration of aspirin may lead to reduced levels of circulating miR-126. Thus, the use of platelet inhibitors should be taken into account when using plasma levels of miR-126 as a biomarker.
AIMS: MicroRNA-126 (miR-126) facilitates angiogenesis and regulates endothelial cell function. Recent data suggest that miR-126 can serve as a biomarker for vascular disease. Although endothelial cells are enriched for miR-126, platelets also contain miR-126. In this paper, we investigated the contribution of platelets to the pool of miR-126 in plasma of patients with type 2 diabetes (DM2) and how this is affected by aspirin. METHODS AND RESULTS: In vitro platelet activation resulted in the transfer of miR-126 from the platelet to the plasma compartment, which was prevented by aspirin. In vivo platelet activation, monitored in patients with DM2 by measuring soluble P-selectin, correlated directly with circulating levels of miR-126. The administration of aspirin resulted both in platelet inhibition and concomitantly reduced circulating levels of platelet-derived microRNAs including miR-126. CONCLUSION: Platelets are a major source of circulating miR-126. Consequently, in patho-physiological conditions associated with platelet activation, such as diabetes type 2, the administration of aspirin may lead to reduced levels of circulating miR-126. Thus, the use of platelet inhibitors should be taken into account when using plasma levels of miR-126 as a biomarker.
Entities:
Keywords:
aspirin; diabetes mellitus type 2; miR-126; platelets
Authors: David D McManus; Kahraman Tanriverdi; Honghuang Lin; Nada Esa; Menhel Kinno; Divakar Mandapati; Stanley Tam; Okike N Okike; Patrick T Ellinor; John F Keaney; J Kevin Donahue; Emelia J Benjamin; Jane E Freedman Journal: Heart Rhythm Date: 2014-10-09 Impact factor: 6.343
Authors: David D McManus; Honghuang Lin; Kahraman Tanriverdi; Michael Quercio; Xiaoyan Yin; Martin G Larson; Patrick T Ellinor; Daniel Levy; Jane E Freedman; Emelia J Benjamin Journal: Heart Rhythm Date: 2014-01-18 Impact factor: 6.343
Authors: Roel Bijkerk; Coen van Solingen; Hetty C de Boer; Pieter van der Pol; Meriem Khairoun; Ruben G de Bruin; Annemarie M van Oeveren-Rietdijk; Ellen Lievers; Nicole Schlagwein; Danielle J van Gijlswijk; Marko K Roeten; Zeinab Neshati; Antoine A F de Vries; Mark Rodijk; Karin Pike-Overzet; Yascha W van den Berg; Eric P van der Veer; Henri H Versteeg; Marlies E J Reinders; Frank J T Staal; Cees van Kooten; Ton J Rabelink; Anton Jan van Zonneveld Journal: J Am Soc Nephrol Date: 2014-03-07 Impact factor: 10.121